<DOC>
	<DOCNO>NCT00767520</DOCNO>
	<brief_summary>The purpose study determine whether exemestane plus dasatinib well-tolerated increase progression-free survival ( PFS ) treatment advance estrogen-receptor positive ( ER+ ) breast cancer disease progression ( PD ) non-steroidal aromatase inhibitor ( NSAI ) .</brief_summary>
	<brief_title>Safety Efficacy Exemestane Plus Dasatinib Versus Placebo Advanced ER+ Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Histologicallydocumented invasive estrogen receptor positive breast cancer , tumor tissue prior surgery available analysis Prior therapy nonsteroidal aromatase inhibitor Recurrent progressive advance breast cancer ( locallyadvanced metastatic ) Documented breast cancer tumor ≤ 28 day prior study entry Women NOT childbearing potential Must able take oral medication Performance Status 0 1 Pleural pericardial effusion ascites ( etiology ; Grade ≥ 1 ) within 6 month prior study entry Any chemotherapy , immunotherapy &lt; 6 month study entry . Any targeted therapy ( eg . lapatinib ) &lt; 6 month study entry , unless give combination NSAI Any antitumor therapy , include radiotherapy hormonal therapy , within 15 day prior study entry Prior exposure exemestane , Srcfamily kinase inhibitor include dasatinib , agent intend control osteolytic disease bisphosphonates , investigational agent breast cancer Concurrent previous malignant disease require chemotherapy radiation treatment within prior 3 year Significant bleed disorder , ongoing recent clinicallysignificant gastrointestinal bleeding Any serious cardiac condition , include congestive heart failure myocardial infarction within 6 month , uncontrolled angina , Class III IV heart disease define New York Heart Association , baseline ejection fraction ≤ 40 % , diagnose congenital long QT syndrome , clinicallysignificant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de Pointes ) , QTc interval &gt; 450 msec baseline ( Fridericia correction ) Hematologic abnormality Grade ≥ 2 Hypocalcemia Grade ≥ 1 Any Chemistry abnormality Grade ≥ 2 [ except Grade 2 indirect bilirubin permit diagnosed Gilbert 's disease ] Pregnant Women Women Childbearing Potential ( WOCBP ) Extremely lactose intolerant , judgment treat physician ( 100 mg dasatinib contain 135 mg lactose , pose problem intolerance severe ) Receiving follow concomitant medication : Category I drug generally accept risk cause Torsades de Pointes include : ( Subjects must discontinue drug use least 7 day prior start dasatinib ) Potent inhibitor CYP3A4 isoenzyme Prisoners subject involuntarily incarcerate ; subject compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Advanced Estrogen Receptor Positive Breast Cancer</keyword>
</DOC>